New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report

Eudald Felip; Laia Llobera; Clara Perez-Mañá; David Quintela; Ignacio Guasch; Mireia Margelí; Iris Teruel; Beatriz Cirauqui; Carmen Centeno; Margarita Romeo; Ester Ballana; Vanesa Quiroga

doi:10.1159/000504618

New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report

Eudald Felip, Laia Llobera, Clara Perez-Mañá, David Quintela, Ignacio Guasch, Mireia Margelí, Iris Teruel, Beatriz Cirauqui, Carmen Centeno, Margarita Romeo, Ester Ballana, Vanesa Quiroga

Department of Pharmacology, Therapeutics and Toxicology

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities.

CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission.

CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.

Original language	English
Pages (from-to)	548-552
Number of pages	5
Journal	Breast Care
Volume	15
Issue number	5
DOIs	https://doi.org/10.1159/000504618
Publication status	Published - Oct 2020

Keywords

Case report
Palbociclib
Pneumonitis
Drug-related pneumonitis
Lung toxicity

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000504618Licence: C In Copyright

Cite this

@article{7fc9e8bf4375413190c0d4b0877cbe7c,

title = "New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report",

abstract = "BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities.CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission.CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.",

keywords = "Case report, Palbociclib, Pneumonitis, Drug-related pneumonitis, Lung toxicity",

author = "Eudald Felip and Laia Llobera and Clara Perez-Ma{\~n}{\'a} and David Quintela and Ignacio Guasch and Mireia Margel{\'i} and Iris Teruel and Beatriz Cirauqui and Carmen Centeno and Margarita Romeo and Ester Ballana and Vanesa Quiroga",

note = "Copyright {\textcopyright} 2019 by S. Karger AG, Basel.",

year = "2020",

month = oct,

doi = "10.1159/000504618",

language = "English",

volume = "15",

pages = "548--552",

journal = "Breast Care",

issn = "1661-3791",

number = "5",

}

TY - JOUR

T1 - New Drugs, Old Toxicities

T2 - Pneumonitis Related to Palbociclib - A Case Report

AU - Felip, Eudald

AU - Llobera, Laia

AU - Perez-Mañá, Clara

AU - Quintela, David

AU - Guasch, Ignacio

AU - Margelí, Mireia

AU - Teruel, Iris

AU - Cirauqui, Beatriz

AU - Centeno, Carmen

AU - Romeo, Margarita

AU - Ballana, Ester

AU - Quiroga, Vanesa

PY - 2020/10

Y1 - 2020/10

N2 - BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities.CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission.CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.

AB - BACKGROUND: Palbociclib is a specific inhibitor of cyclin-dependent kinases 4 and 6 that is approved for the treatment of advanced or metastatic breast cancer patients. Despite a good toxicity profile in pivotal trials, where asymptomatic neutropenia was the main adverse effect, its wider use in clinical practice may show less prevalent but serious toxicities.CASE PRESENTATION: Here, we describe a case of pneumonitis due to palbocicblib. A 57-year-old female with breast cancer with bone metastasis presented dyspnea at rest 3 months after beginning treatment with palbociclib and letrozole. Palbociclib-induced pneumonitis was considered the most probable cause after ruling out all alternatives, and the patient was successfully treated with steroids and showed complete remission.CONCLUSIONS: In summary, we present a well-documented case report of pneumonitis related to palbociclib. However, the mechanism of toxicity is still unknown, and there are as yet no reliable biomarkers to predict toxicity with cyclin-dependent kinase 4/6 inhibitors. In this case report, we alert physicians about new drugs that can provoke old toxicities.

KW - Case report

KW - Palbociclib

KW - Pneumonitis

KW - Drug-related pneumonitis

KW - Lung toxicity

U2 - 10.1159/000504618

DO - 10.1159/000504618

M3 - Article

C2 - 33224001

SN - 1661-3791

VL - 15

SP - 548

EP - 552

JO - Breast Care

JF - Breast Care

IS - 5

ER -

New Drugs, Old Toxicities: Pneumonitis Related to Palbociclib - A Case Report

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this